Fragment 176-191Also known as: hGH Fragment 176-191, GH Frag 176-191, Human Growth Hormone Fragment 176-191

Mechanism of Action

Fragment 176-191 is a synthetic peptide derivative of the human growth hormone (hGH) that mimics the region from amino acids 176 to 191 of the hGH molecule. It specifically stimulates lipolysis by activating the signaling pathways in fat cells that increase the breakdown of triglycerides into free fatty acids and glycerol, without the broader diabetogenic effects associated with full-length hGH. This peptide enhances mitochondrial activity and energy expenditure in adipocytes, leading to fat loss without significantly affecting blood glucose levels.

Reported Research Benefits

Primarily researched for its fat loss and lipolytic properties. Used in studies related to obesity, body fat reduction, and metabolic enhancement. It is also examined for its potential to increase energy expenditure and to improve body composition without the negative side effects of full-length growth hormone administration.

Dosing Protocol & Reconstitution

Typical experimental doses in research settings range around 100 mcg administered subcutaneously prior to exercise or cardio sessions to enhance fat burning. Exact dosing protocols vary, but low microgram doses are common to avoid adverse effects and to target fat metabolism specifically.

Research Notes

Fragment 176-191 exhibits a longer half-life compared to native hGH in terms of fat metabolism effects, with some studies showing improvements in fat loss with minimal impact on glucose metabolism. It is often studied in combination with other peptides or compounds to assess synergistic effects for fat reduction. The peptide is delivered as a lyophilized powder requiring reconstitution (often with bacteriostatic water) prior to experimental use.

Research Summary

Fragment 176-191, a synthetic peptide derived from human growth hormone, has been primarily studied in preclinical animal models where it demonstrated a significant ability to stimulate lipolysis and reduce adipose tissue without causing the hyperglycemic effects commonly associated with full-length hGH. Evidence from rodent studies indicates enhanced mitochondrial activity and increased energy expenditure in adipocytes, leading to reductions in body fat. However, clinical research in humans is limited, and controlled trials that rigorously evaluate its efficacy and safety are lacking, which restricts definitive conclusions about its therapeutic potential and applicability.

Side Effects & Safety

Safety data for Fragment 176-191 is largely extrapolated from animal studies, with limited direct human evidence. Commonly theoretical side effects include injection site reactions and unknown long-term metabolic effects, given the peptide’s mechanism on fat metabolism. There is a potential risk of undesired lipolytic activity or interference with endogenous hormone regulation. No significant drug interactions have been well-characterized. Fragment 176-191 is not approved by regulatory agencies and is banned by the World Anti-Doping Agency (WADA) for use in competitive sports due to its performance-enhancing potential. Caution is advised especially in populations with metabolic or endocrine disorders.

Stability & Storage

Refer to research notes

Molecular Data

Sequence: LQGVLPALPQVVCYASN
Molecular Formula: C90H137N23O24
Molecular Weight: 2010.37 g/mol

Primary literature: https://pubmed.ncbi.nlm.nih.gov/?term=Fragment+176-191